Navigation Links
ENCO Pharmaceutical Development Announces Another Successful FDA Inspection - Its 2nd This Year
Date:3/20/2013

JACKSONVILLE, Fla., March 20, 2013 /PRNewswire-iReach/ --  ENCO Pharmaceutical Development's Jacksonville, FL Facility Completes Successful FDA Audit

ENCO Pharmaceutical Development, Inc. (EPDI) is pleased to announce the completion of a successful FDA inspection of its Jacksonville FL facility.  The audit was a directed Pre-approval Inspection (PAI). 

The audit occurred between March 7th and 8th, 2013.  Upon the completion of the inspection, the investigator reported no findings and no Form 483 was issued.

"As a company we understand the value of maintaining a high level of compliance," said Mark Inman , Ph.D., VP and Director of Quality Assurance.  "Not only do we want to ensure adherence to the existing regulatory requirements, EPDI also remains connected to the various regulatory bodies we work with to keep the company at the forefront of changes in the regulatory industry."

This audit marks the second consecutive month that an EPDI facility has been audited by the FDA.  In February, auditors inspected EPDI's Cary, NC facility.  "Between the two audits, our company has experienced nearly 5 days of intensive inspection by the FDA with no 483's or observations to report," Mark Inman continued. 

The audit covered thorough reviews of general systems such as training, equipment calibration/qualification, SOP's, protocols and methods and involved a variety of technical areas including analytical development and release testing.

ENCO Pharmaceutical Development Inc. provides a broad spectrum of pharmaceutical development and analytical services from its facilities in Jacksonville, FL and Cary, NC.  The company works with a variety of organizations in both the pharmaceutical and medical device industries, including global, small and mid-size firms, as well as virtual organizations. EPDI provides expertise in formulation development of solid, semi-solid, liquids, ophthalmic and lyophilized dosage forms as well as analytical support for method development and validation, stability studies, raw materials testing, extractable/leachable studies, medical device testing and more. For additional information, please visit www.encopharma.com.

Media Contact: Keith Hurley , ENCO Pharmaceutical Development, Inc., 336.541.3270, khurley@encopharma.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE ENCO Pharmaceutical Development, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
2. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
3. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
4. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
5. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. Thomson Reuters Launches New Mobile Oncology Decision Support Solution for R&D Pharmaceutical Leaders
8. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
9. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
10. Icahn Issues Statement Regarding Amylin Pharmaceuticals
11. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... 4, 2017  According to the Centers for Disease Control and Prevention ... . PhysicianOne Urgent Care is helping communities across Massachusetts ... , by offering no-cost* flu shots through the end of the month. ... health insurance regulations. ... to get a flu shot is by the end of October, according ...
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:10/2/2017)... -- The Rebound mobile app is poised to become a ... of prescription drug addiction. The app empowers users to develop ... down their dosage in a safe, controlled manner while maximizing ... first 100,000 people to sign up will enjoy 3 months ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
(Date:10/13/2017)... , ... October 13, 2017 , ... The Visiting Nurse ... Market. Featuring a collection of specialty vendors and unique items from across the nation, ... quality-focused health and wellness services offered by the VNA. The boutique will be ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... , ... Planet Fitness, one of the largest and fastest growing franchisors and ... flagship location in Covington, LA at 401 N. U.S. Highway 190, in January of ... Depot in the Holiday Square shopping center. Its location allows it to serve both ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):